Improved resources to guide MS management

Dr Claudia Marck

University of Melbourne, VIC

January 2021

Specialisation: Social And Applied Research

focus area: Better treatments

funding type: Fellowship

project type: Investigator Led Research

Summary

Managing MS well requires self-management skills, including decision-making skills. It also requires considerable guidance and teaching from healthcare professionals on health and wellness strategies. However, current gaps in the availability and quality of resources in this area can make decision-making for people living with MS challenging. The need for smoking cessation is an example of an area of MS care which has received a lot of attention in recent times, but there is little in the way of direct guidance for people living with MS to stop smoking successfully. 

Associate Professor Claudia Marck’s research aimed to uncover these gaps and help develop resources to promote safer and more effective outcomes for people living with MS. There are several areas of focus in this research. Associate Professor Marck aimed to develop smoking cessation resources specifically for the MS community. Additionally, the team developed new statistical methods to assess the effectiveness of different MS treatments such as psychological interventions and physical activity, not just medications. Associate Professor Marck also focused on these treatments and their impact on common MS symptoms, such as walking impairment, depression and fatigue. In her research, Associate Professor Marck also hoped to more deeply understand how self-management skills and access to healthcare may be impacted by crises, such as the recent Australian bushfires and the COVID-19 pandemic. 

Outcomes from this research will assist both healthcare professionals working in MS, and people living with MS, to access appropriate resources to promote self-management, decision making and wellness, improving both quality of life and health in general. 

Outcome

Associate Professor Claudia Marck’s fellowship explored several connected areas aimed at improving care and wellbeing for people living with MS.  

A major focus was smoking cessation, where an umbrella review of 11 reviews covering 97 studies found strong evidence that active smoking increases MS risk and worsens disability progression. Building on this, the team developed and tested an MS-specific smoking cessation program with 48 people with MS in Germany, where smoking rates are high. The program was well received, with nearly all participants recommending it to others, and some remained smoke free at 12 weeks. Because smoking is strongly linked to worse MS outcomes, this work highlights the potential health benefits of tailored support to help people with MS quit. 

The fellowship also examined other important areas of MS care. A review of treatments for depressive symptoms in MS found that the available evidence was low quality, meaning clear comparisons between treatment options could not be made. In response, the team made recommendations to improve future clinical trials so that treatments can be assessed more meaningfully.  

In the area of physical activity and exercise, a review of 18 clinical trials found that exercise can lead to small but meaningful reductions in anxiety symptoms for people with MS. Another review showed that while physical activity guidelines for MS exist, they are not always practical or easy to apply in everyday healthcare, pointing to the need for clearer and more usable guidance. 

Research into clinical guideline implementation showed that existing guidelines are valued by MS clinicians for supporting consistent care, but there are challenges in applying them to complex real-world situations. After interviewing 16 MS clinicians, the team developed evidence-based recommendations to support better uptake and inform future guideline development.  

The fellowship also identified substantial unmet needs in crisis preparedness among Australians with MS. In response, a Crisis Toolkit was co-designed with the Australian Red Cross and people with MS. Testing showed that the toolkit was well accepted and helped improve confidence, resilience and preparedness, while reducing distress. 

Together, this work provides evidence-based, person-centred approaches to help people with MS make informed decisions, strengthen self-management, maintain access to care, and support better health and quality of life.  

During the fellowship, Associate Professor Marck also built several collaborations and produced numerous publications, with findings presented at the European RIMS conference and the MS Nurses Australasia conference. 

publications

  1. Weld-Blundell I, Learmonth YC, Klaic M, Ayton D, Haartsen J, Kermode A, Probst Y, Heesen C, Marck CH (2026). The application of treatment guidelines in multiple sclerosis care: a qualitative analysis of barriers and facilitators. International journal of MS Care 28 (1), 1-12 
  2. Poli, S., Kos, D., Evangelou, N., Freeman, J., Brichetto, G.,Podda, J., Susini A, Grange E, Guidotti V, BurlandoM, Mesmaeker S, Swain P, Janssen D, Finlayson M, Bozzoli F, Bo L, Dalgas U, Farrin A, Wright-Hughes A, Jidborg H, Marck CH, Ontaneda D, Rimondini M, Taylor L, das Nair R. (2025). Testing a Goal-Oriented personalized, holistic wellbeing intervention: Case Studies from Belgium, Italy, and UK of the Living Well Program for Progressive MS. Multiple Sclerosis Journal, 31(3), 70-70. 
  3. Tan J, Marck CH,GalnaB, Laslett LL, van der Mei I, Learmonth YC (2025) The impact of COVID-19 on medical care and health service access in persons with multiple sclerosis–A cross-sectional study from the Australian MS Longitudinal Study. Multiple Sclerosis and Related Disorders, 2026;105:106877 
  4. Keller AM, Kotz D, Marck CH,WöhlerA, Heesen C, Riemann-Lorenz K. (2025) Smoking and multiple sclerosis: Development and feasibility study of a MS-specific smoking cessation intervention. Therapeutic Advances in Neurological Disorders 18, 17562864251391057 
  5. Finlayson M PS, Bozzoli F, Brichetto G,BøL, Busch IM, Dalgas U, Evangelou N, Farrin A, Freeman J, Jidborg H, Kos D, Marck CH, Ontaneda D, Podda J, Rimondini M, Swain P, Tallantyre E, Taylor LA , das Nair R. (2025) Designing wellbeing intervention trials for people with progressive multiple sclerosis: The importance of understanding “usual care” comparators. International journal of MS Care https://doi.org/10.7224/1537-2073.2024-099 
  6. Tan J, Marck C, Martin-Lynch P, Skeffington P, Walker D, Gibbs L, Learmonth Y (2025) Disaster Preparation forPeopleWith Multiple Sclerosis: A Scoping Review of Resources. International Journal of MS Care 27: 186-197 
  7. Riemann-Lorenz K, Krause N, Marck CH,DaubmannA, Heesen C (2025) Diet and multiple sclerosis – development and mixed methods feasibility testing of a comprehensive nutritional information resource (NUTRIMS). Disabil Rehabil 47:1988-1999 
  8. Marck CH, Weld-Blundell IV,KlaicM, Motl RW, Learmonth YC (2025) The Actionability of Physical Activity Guidelines for Multiple Sclerosis Care: A Systematic Review and AACTT Framework Analysis. Arch Phys Med Rehabil 106:590-606 
  9. Learmonth YC, Hawkins MR, Karahalios A, Skeffington P, Wood EJ, Marck CH (2025) The effect of exerciseinterventions on symptoms of anxiety in persons with multiple sclerosis: a systematic review and meta-analysis. MultScler Relat Disord 103:106709 
  10. Keller AM, Marck CH, Kotz D, von Glasenapp B, Heesen C, Riemann-Lorenz K (2025) Smoking cessation inpeople with multiple sclerosis: qualitative study on the current practices and barriers for deliveringassistance from the perspective of healthcare professionals in Germany. BMJ Open 15:e091950 
  11. Motl RW, Russell DI,PiluttiLA, Metse AP, Marck CH, Chan B, Zheng P, Learmonth YC (2024) Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report. Mult Scler 30:605-611 
  12. Marck CH,GalnaB, van der Mei IAF, Laslett LL, Tan J, Gibbs L, Kermode AG, Walker DI, Learmonth YC (2024) Crisis preparation for people with multiple sclerosis in Australia: A cross-sectional survey of needs. International Journal of Disaster Risk Reduction 109:104586 
  13. Learmonth YC,GalnaB, Laslett LL, van der Mei I, Marck CH (2024) Improving telehealth for persons with multiple sclerosis – a cross-sectional study from the Australian MS longitudinal study. Disabil Rehabil 46:4755-4762 
  14. Learmonth YC, Bhoyroo R, Gibbs L, Kermode A, Walker D, Marck CH (2024) Multiple Sclerosis and COVID-19:Health and healthcare access, healthinformation and consumer co-created strategies for future access at times of crisis. Mult Scler Relat Disord 87:105691 
  15. Keller AM, von Glasenapp B, Kotz D, Marck CH, Heesen C, Riemann-Lorenz K (2024) Motivators and barriersfor smoking cessation in people with multiple sclerosis: a qualitative study to inform the design of a tailoredintervention. BMC Public Health 24:3402 
  16. Campese S, Lyons J, Learmonth YC,MetseA, Kermode AG, Marck CH, Karahalios A (2024) Comparing the effectiveness, safety and tolerability of interventions for depressive symptoms in people with multiple sclerosis: A systematic review. Mult Scler Relat Disord 89:105763 
  17. Motl RW, Casey B, Learmonth YC, Latimer-Cheung A, Kinnett-Hopkins DL, Marck CH, Carl J, Pfeifer K,Riemann-Lorenz K, Heesen C, Coote S (2023) TheMoXFo initiative – adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research. Mult Scler 29:1595-1603 
  18. Learmonth YC, M PH, Russell DI,PiluttiLA, Day S, Marck CH, Chan B, Metse AP, Motl RW (2023) Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis. Mult Scler 29:1604-1631 
  19. Learmonth YC, Hunter A, Gibbs L, Walker D, Kermode AG, Marck CH (2023) The impact of the Australian BlackSummer Bushfires and the COVID-19 pandemic on wellbeing in persons with multiple sclerosis; preparation forfuture and ongoing crises. Disabil Rehabil 45:630-643 
  20. Learmonth YC, Heritage B, Marck CH, Chen J, van der Mei I (2023) Physical activity participation in Australianswith multiple sclerosis: associations with geographical remoteness.Disabil Rehabil 45:1969-1974 
  21. Learmonth YC, Assunta H, Skeffington P, Diana W, Kermode AG, Marck CH (2023) Healthcare complexitiesduring community crises: Recommendation for access to healthcare for Australians with multiple sclerosis. MultScler Relat Disord 71:104531 
  22. Weld-Blundell IV, Grech L, Learmonth YC, Marck CH (2022) Lifestyle and complementary therapies in multiplesclerosis guidelines: Systematic review. Acta Neurol Scand 145:379-392
  23. Weld-Blundell I, Grech L, Borland R, White SL, das Nair R, Marck CH (2022) Smoking habits,awarenessand support needs for cessation among people with multiple sclerosis in Australia: findings from an online survey. BMJ Open 12:e059637 
  24. Marck CH, Learmonth YC, Chen J, van der Mei I (2022) Physical activity, sitting time and exercise types, andassociations with symptoms in Australian people with multiple sclerosis.Disabil Rehabil 44:1380-1388 
  25. Lyons J, Campese S, Learmonth YC,MetseA, Kermode AG, Karahalios A, Marck CH (2022) Comparing the effectiveness, safety and tolerability of interventions for depressive symptoms in people with multiple sclerosis: a systematic review and network meta-analysis protocol. BMJ Open 12:e055796 
  26. Dobson R, Rice DR,D’HoogheM, Horne R, Learmonth Y, Mateen FJ, Marck CH, Reyes S, Williams MJ, Giovannoni G, Ford HL (2022) Social determinants of health in multiple sclerosis. Nat Rev Neurol 18:723-734 
  27. Marck CH, Probst Y, Chen J, Taylor B, van der Mei I (2021) Dietary patterns and associations with healthoutcomes in Australian people with multiple sclerosis.Eur J Clin Nutr 75:1506-1514 
  28. Marck CH, Hunter A, Heritage B, Gibbs L, Kermode AG, Walker DI, Learmonth YC (2021) The effect of theAustralian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis. MultScler Relat Disord 53:103042 

Updated 31 March 2026

lead investigator

total funding

$165,000

start year

2021

duration

3 years

STATUS

Past project

Stages of the research process

Fundamental laboratory Research

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline

10+ years

Translational Research

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline

5+ years

Clinical Studies and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline

3+ years

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Improved resources to guide MS management